Goldman Sachs initiated coverage of DexCom (DXCM) with a Buy rating and $104 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and DexCom offers potential upside from consumer-related adoption and strong profitability leverage that should evidence through the balance of 2025, the analyst tells investors in a research note. The market also underappreciates the degree of P&L upside in DexCom model as gross margins scale, Goldman Sachs added.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target raised to $102 from $82 at Citi
- Dexcom’s Strategic Advancements and Market Opportunities Justify Buy Rating with $105 Price Objective
- Dexcom Promotes Jacob S. Leach to President and COO
- Dexcom Stockholders Approve Equity Plan Amendments
- DexCom price target raised to $93 from $90 at Barclays